# Study to Confirm of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney Transplantation

> **NCT05511779** · PHASE2 · TERMINATED · sponsor: **SymBio Pharmaceuticals** · enrollment: 1 (actual)

## Conditions studied

- BK Virus Infection
- Nephropathy
- Kidney Transplantation

## Interventions

- **DRUG:** Brincidofovir

## Key facts

- **NCT ID:** NCT05511779
- **Lead sponsor:** SymBio Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-10-14
- **Primary completion:** 2023-04-13
- **Final completion:** 2023-04-13
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Due to delays in enrollment
- **Last updated:** 2024-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05511779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05511779, "Study to Confirm of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney Transplantation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05511779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*